Table 1.
Summarized clinical information (details in Supplementary Table 1).
| MuSK-MG | AChR-MG | Non-disease controls | |
|---|---|---|---|
| Female, n (%) | 45 (86.54%) | 22 (51.16%) | 38 (82.61%) |
| Male, n (%) | 7 (13.46%) | 21 (48.84%) | 8 (17.39%) |
| Age at sample, median (range) | 49 (17–79) | 63 (2–82) | 47.8 (20–68) |
| Age of onset, median (range) | 43 (10–79) | 62 (1–82) | |
| General immune therapy, n (%) | 39 (75%)/44 84.62%)* | 28 (65.1%) | |
| Oral corticosteroids (prednisone, dexamethasone) | 26 (50%) | 19 (44.19%) | |
| Prednisone and azathioprine | 7 (13.46%) | 6 (13.95%) | |
| Prednisone and IVIG | 3 (5.77%) | 0 | |
| Prednisone, plasmapheresis | 2 (3.85%) | 0 | |
| Azathioprine only | 1 (1.92%) | 0 | |
| Other combinations (see Supplementary Table 1) | 5 (9.62%) | 3 (6.98%) | |
| Thymectomy | 5 (9.61%) | 7 (16.28%) |
*Five patients with MuSK-MG from Greece had samples before and after treatment (details in Table 2).